Allogene Therapeutics (ALLO) Share-based Compensation (2018 - 2026)

Allogene Therapeutics has reported Share-based Compensation for 9 years, with the latest figure at $8.3 million in Q1 2026.

• Quarterly Share-based Compensation fell 32.07% year-over-year to $8.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.9 million (down 106.35% YoY) and the FY2024 annual result came in at $51.7 million, changed N/A from the prior year.
• Share-based Compensation improved to $8.3 million in Q1 2026 per ALLO's latest filing, from -$12.2 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $36.5 million in Q3 2024 and troughed at -$35.4 million in Q3 2023.
• A 5-year average of $7.0 million and a median of $12.9 million in 2024 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2023 and 2025: Share-based Compensation slumped 267.22% in 2023, then jumped 405.4% in 2025.
• Over 5 years, Share-based Compensation stood at -$35.0 million in 2022, then dropped by 1.06% to -$35.4 million in 2023, then jumped by 136.4% to $12.9 million in 2024, then slumped by 194.58% to -$12.2 million in 2025, then surged by 167.93% to $8.3 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $8.3 million, -$12.2 million, and $12.2 million for Q1 2026, Q2 2025, and Q1 2025 respectively.